| Authors: |
Bagal SK; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Astles PC; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Diène C; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Argyrou A; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Crafter C; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Cassar DJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Fallan C; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Hock A; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Jones T; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Moreau K; Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge CB4 0WG, U.K., Lamont GM; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Lamont S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Michaloglou C; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Packer MJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Pike A; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Ramos-Montoya A; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Scott JS; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Shaw J; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Shologu Z; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K. |